A total of 500 respondents with indicated a 49.1% preference for the mode and frequency of administration when choosing between oral and injectable .
Oral semaglutide profiles were significantly preferred over injectable options, with 91.0% choosing the 7 mg profile over dulaglutide.
The 14 mg oral semaglutide profile was preferred by 94.4% of respondents compared to liraglutide.
Willingness to initiate treatment was higher for oral formulations, with 62.4% for the 7 mg and 64.0% for the 14 mg profiles.
In contrast, only 13.6% and 11.0% expressed willingness for injectable GLP-1 receptor agonist profiles.
Nausea risk, weight change, and HbA1c change were also important factors in the decision-making process.
Simplified
INTRODUCTION: Glucagon-like peptide 1 (GLP-1) receptor agonists () approved to date are administered by injection; therefore, patient perceptions of an oral GLP-1 RA are unknown. This discrete choice experiment explored preferences for (unbranded) oral and injectable GLP-1 RA profiles among Japanese patients with (T2D).
METHODS: An online survey was designed using literature review and qualitative interview findings, and administered to Japanese patients with T2D and HbA ≥ 7.0% receiving oral antiglycaemic medication (with no experience of injectable antiglycaemic medication). Therapy profiles were created using Japanese head-to-head trial data for orally administered semaglutide (7 mg and 14 mg), injectable dulaglutide (0.75 mg), and injectable liraglutide (0.9 mg). Profiles were not labelled. Choice tasks tested preference between hypothetical profiles, preference between profiles with actual trial data, and willingness to initiate treatment. Relative importance of attributes was determined using conditional logit regression. 1c
RESULTS: A total of 500 respondents were analysed: mean age 61.2 years; 93.8% male; mean HbA7.6%; 78.2% with HbA ≥ 7.0 to < 8%; 89% with HbAabove personal target. Mean BMI was 25.4 kg/m; 49% had obesity (≥ 25 kg/m). The treatment attribute with greatest importance was mode and frequency of administration (49.1%), followed by nausea risk (30.8%), weight change (11.3%), and HbAchange (8.8%). Oral semaglutide 7 and 14 mg-like profiles were both preferred: the 7 mg-like profile was preferred over dulaglutide (by 91.0% of respondents) and liraglutide (by 89.4%); the 14 mg-like profile was preferred over dulaglutide (by 88.2%) and liraglutide (by 94.4%). Willingness to initiate treatment was also higher for orally administered semaglutide-like profiles: 62.4% with 7 mg and 64.0% with 14 mg, versus 13.6% and 11.0% with injectable GLP-1 RA-like profiles. Subgroup results were generally consistent with the overall sample. 1c1c1c1c2 2
CONCLUSION: Japanese patients with T2D appear to prefer oral GLP-1 RA profiles over injectable GLP-1 RA profiles, and administration appears to be the most important factor in this decision. This highlights the unmet need for an effective and orally administered GLP-1 RA for the treatment of T2D in Japan.
Key numbers
89.4–94.4%
Preference for Oral Therapy
Percentage of respondents preferring oral semaglutide profiles vs. injectable dulaglutide or liraglutide profiles.
62.4% with 7 mg and 64.0% with 14 mg
Willingness to Initiate Treatment
Percentage of respondents willing to start treatment with oral semaglutide compared to injectable therapies.
49.1%
Importance of Administration Mode
Percentage of decision-making variance attributed to mode and frequency of administration.
Full Text
We can’t show the full text here under this license.
